Conclusion

Our postapproval, single-center 6-month survival of 93.3% is suggestive of comparable real-world findings when compared with the MOMENTUM 3 trial patients and the data from the ELEVATE registry. However, similar findings through multi-institutional studies are needed to confirm these results.